Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NovaMed gets Chinese rights to Aggrastat from Iroko

Executive Summary

NovaMed Pharmaceuticals (cancer, cardiovascular, neurology, urology, and gynecology therapeutics) has licensed exclusive Chinese rights to Aggrastat (tirofiban) from Iroko (creating new formulations of existing drugs). The glycoprotein IIb/IIIa receptor antagonist is prescribed for myocardial infarction (MI) patients that undergo primary coronary angioplasty.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies